Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL291492 | 0.91 | MEN1 (0.59) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL3368374 | 0.90 | ALDH1A1 (0.69) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL7148678 | 0.90 | MEN1 (0.58) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL28343387 | 0.88 | MEN1 (0.57) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL2779580 | 0.88 | NPC1 (0.59) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL10353075 | 0.85 | MEN1 (0.53) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL3364573 | 0.84 | MAPT (0.52) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL9151227 | 0.81 | MEN1 (0.50) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL3413576 | 0.80 | ALDH1A1 (0.73) | MEN1KMT2AMAPTNPC1RAB9A | |
| SCHEMBL139043 | 0.80 | LMNA (0.59) | MEN1KMT2AMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2727915-B1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | claimed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| EP-4419513-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-12384800-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2025-08-12 | — | — | US | disclosed |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-07-31 | — | — | US | disclosed |
| WO-2025077996-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-04-17 | — | — | WO | disclosed |
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| WO-2024074604-A1 | COMPOUNDS FOR THE MANAGEMENT OF CELL STEMNESS AND INVASION IN CANCER AND RELATED DISEASES | INSTITUTO BIOMAR, S.A (ES) | 2024-04-11 | — | — | WO | disclosed |
| EP-4349409-A1 | COMPOUNDS FOR THE MANAGEMENT OF CELL STEMNESS AND INVASION IN CANCER AND RELATED DISEASES | Instituto Biomar S.A. (ES) | 2024-04-10 | — | — | EP | disclosed |
| US-20080199874-A1 | CONTROLLABLE STRAND SCISSION OF MINI CIRCLE DNA | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080176769-A1 | Articles having localized molecules disposed thereon and methods of producing same | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080153100-A1 | substrates having selected active chemical regions by employing elements of the substrates in assisting the localization of active chemical groups in desired regions of the substrate. The methods may include optical, chemical and/or mechanical processes for deposits | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080050747-A1 | Articles having localized molecules disposed thereon and methods of producing and using same | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080032301-A1 | Articles having localized molecules disposed thereon and methods of producing same | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080009007-A1 | CONTROLLED INITIATION OF PRIMER EXTENSION | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| WO-2007144423-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007123763-A2 | ARTICLES HAVING LOCALIZED MOLECULES DISPOSED THEREON AND METHODS OF PRODUCING SAME | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070238679-A1 | Articles having localized molecules disposed thereon and methods of producing same | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384800-B2 | Antitumoral compounds | TP53, TOP1, MCL1 | MEN1 246/4885KMT2A 4002/4885MAPT 4519/4885 |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | MCL1, XPOT, GZMB | MEN1 245/4885KMT2A 3001/4885MAPT 4578/4885 |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | MEN1 3189/4885KMT2A 450/4885MAPT 8/4885 |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | TP53, TOP1, MCL1 | MEN1 246/4885KMT2A 4002/4885MAPT 4519/4885 |
| US-12215100-B2 | Anticancer compounds | TP53, MCL1, MYC | MEN1 1162/4885KMT2A 3314/4885MAPT 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.